CYTH logo

Cyclo Therapeutics (CYTH) Company Overview

Profile

Full Name:

Cyclo Therapeutics, Inc.

Sector:

Healthcare

Country:

United States

IPO:

May 3, 2000

Indexes:

Not included

Description:

Cyclo Therapeutics (CYTH) is a biotechnology company focused on developing innovative treatments for diseases, particularly those related to the brain. They specialize in using a unique drug delivery system to improve the effectiveness of therapies for conditions like Alzheimer’s disease and other neurodegenerative disorders.

Events Calendar

Earnings

Next earnings date:

Mar 18, 2025

Recent quarterly earnings:

Nov 14, 2024

Recent annual earnings:

Mar 18, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Dec 9, 2020

Analyst ratings

Recent major analysts updates

Aug 27, 24 Maxim Group
Hold
Aug 26, 24 Ascendiant Capital
Buy
Aug 23, 24 HC Wainwright & Co.
Neutral
Aug 16, 24 HC Wainwright & Co.
Buy
May 31, 24 HC Wainwright & Co.
Buy
May 1, 24 HC Wainwright & Co.
Buy
Apr 22, 24 Ascendiant Capital
Buy
Sep 27, 23 Maxim Group
Buy
Mar 21, 23 Maxim Group
Hold
Dec 17, 20 Maxim Group
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

FAQ

  • What is the ticker symbol for Cyclo Therapeutics?
  • Does Cyclo Therapeutics pay dividends?
  • What sector is Cyclo Therapeutics in?
  • What industry is Cyclo Therapeutics in?
  • What country is Cyclo Therapeutics based in?
  • When did Cyclo Therapeutics go public?
  • Is Cyclo Therapeutics in the S&P 500?
  • Is Cyclo Therapeutics in the NASDAQ 100?
  • Is Cyclo Therapeutics in the Dow Jones?
  • When was Cyclo Therapeutics's last earnings report?
  • When does Cyclo Therapeutics report earnings?
  • Should I buy Cyclo Therapeutics stock now?

What is the ticker symbol for Cyclo Therapeutics?

The ticker symbol for Cyclo Therapeutics is NASDAQ:CYTH

Does Cyclo Therapeutics pay dividends?

No, Cyclo Therapeutics does not pay dividends

What sector is Cyclo Therapeutics in?

Cyclo Therapeutics is in the Healthcare sector

What industry is Cyclo Therapeutics in?

Cyclo Therapeutics is in the Drug Manufacturers - Specialty & Generic industry

What country is Cyclo Therapeutics based in?

Cyclo Therapeutics is headquartered in United States

When did Cyclo Therapeutics go public?

Cyclo Therapeutics's initial public offering (IPO) was on May 3, 2000

Is Cyclo Therapeutics in the S&P 500?

No, Cyclo Therapeutics is not included in the S&P 500 index

Is Cyclo Therapeutics in the NASDAQ 100?

No, Cyclo Therapeutics is not included in the NASDAQ 100 index

Is Cyclo Therapeutics in the Dow Jones?

No, Cyclo Therapeutics is not included in the Dow Jones index

When was Cyclo Therapeutics's last earnings report?

Cyclo Therapeutics's most recent earnings report was on Nov 14, 2024

When does Cyclo Therapeutics report earnings?

The next expected earnings date for Cyclo Therapeutics is Mar 18, 2025

Should I buy Cyclo Therapeutics stock now?

As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions